Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome

被引：35

作者：

Fakhouri, Fadi ^{[1
,2
]}

Loirat, Chantal ^{[3
]}

机构：

[1] Univ Nantes, INSERM, Ctr Rech Transplantat & Immunol, Dept Nephrol,UMR 1064, Nantes, France

[2] CHU Nantes, Nantes, France

[3] Sorbonne Paris Cite, Univ Paris Diderot, Hop Univ Robert Debre, AP HP,Dept Pediat Nephrol, Paris, France

来源：

SEMINARS IN HEMATOLOGY | 2018年 / 55卷 / 03期

关键词：

MONITORING ECULIZUMAB TREATMENT; INVASIVE MENINGOCOCCAL DISEASE; COMPLEMENT FUNCTIONAL TESTS; FACTOR-H AUTOANTIBODY; THROMBOTIC MICROANGIOPATHY; PEDIATRIC-PATIENTS; FOLLOW-UP; ACTIVATION; OUTCOMES; THERAPY;

D O I：

10.1053/j.seminhematol.2018.04.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The dissection of the pathogenic mechanisms of the various forms of the hemolytic uremic syndrome (HUS) has paved the way for the design of specific efficacious treatments. Such mechanistic approach led to a revolution in the management of atypical HUS with the use of the first-in class C5 blocker, eculizumab. The availability of this anticomplement drug has also raised unsettled questions regarding the cost or burden and optimal duration of therapy and its use in secondary HUS. The efficacy of eculizumab in Shiga toxin producing Escherichia coli-associated HUS is not to date established and the results of ongoing prospective studies are eagerly awaited. Nevertheless, the emergence of anticomplement therapies (eculizumab and other drugs in development) has transformed our approach of HUS. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：150 / 158

页数：9

共 88 条

[31] Epidemic Profile of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany [J].

Frank, Christina ;

Werber, Dirk ;

Cramer, Jakob P. ;

Askar, Mona ;

Faber, Mirko ;

an der Heiden, Matthias ;

Bernard, Helen ;

Fruth, Angelika ;

Prager, Rita ;

Spode, Anke ;

Wadl, Maria ;

Zoufaly, Alexander ;

Jordan, Sabine ;

Kemper, Markus J. ;

Follin, Per ;

Muller, Luise ;

King, Lisa A. ;

Rosner, Bettina ;

Buchholz, Udo ;

Stark, Klaus ;

Krause, Gerard .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (19) :1771-1780

[32] Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults [J].

Fremeaux-Bacchi, Veronique ;

Fakhouri, Fadi ;

Gamier, Arnaud ;

Bienaime, Frank ;

Dragon-Durey, Marie-Agnes ;

Ngo, Stephanie ;

Moulin, Bruno ;

Servais, Aude ;

Provot, Francois ;

Rostaing, Lionel ;

Burtey, Stephane ;

Niaudet, Patrick ;

Deschenes, Georges ;

Lebranchu, Yvon ;

Zuber, Julien ;

Loirat, Chantal .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (04) :554-562

[33] Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome [J].

Gaggl, Martina ;

Aigner, Christof ;

Csuka, Dorottya ;

Szilagyi, Agnes ;

Prohaszka, Zoltan ;

Kain, Renate ;

Haninger, Natalja ;

Knechtelsdorfer, Maarten ;

Sunder-Plassmann, Raute ;

Sunder-Plassmann, Gere ;

Schmidt, Alice .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (03) :1020-1029

[34] Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule [J].

Gatault, Philippe ;

Brachet, Guillaume ;

Ternant, David ;

Degenne, Danielle ;

Recipon, Guillaume ;

Barbet, Christelle ;

Gyan, Emmanuel ;

Gouilleux-Gruart, Valerie ;

Bordes, Cecile ;

Farrell, Alexandra ;

Halimi, Jean Michel ;

Watier, Herve .

MABS, 2015, 7 (06) :1205-1211

[35]

Gately R, 2017, NEPHRO SUPPL, V22, P532

[36] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference [J].

Goodship, Timothy H. J. ;

Cook, H. Terence ;

Fakhouri, Fadi ;

Fervenza, Fernando C. ;

Fremeaux-Bacchi, Veronique ;

Kavanagh, David ;

Nester, Carla M. ;

Noris, Marina ;

Pickering, Matthew C. ;

de Cordoba, Santiago Rodriguez ;

Roumenina, Lubka T. ;

Sethi, Sanjeev ;

Smith, Richard J. H. .

KIDNEY INTERNATIONAL, 2017, 91 (03) :539-551

[37] Hemolytic Uremic Syndrome and Death in Persons with Escherichia coli O157:H7 Infection, Foodborne Diseases Active Surveillance Network Sites, 2000-2006 [J].

Gould, L. Hannah ;

Demma, Linda ;

Jones, Timothy F. ;

Hurd, Sharon ;

Vugia, Duc J. ;

Smith, Kirk ;

Shiferaw, Beletshachew ;

Segler, Suzanne ;

Palmer, Amanda ;

Zansky, Shelley ;

Griffin, Patricia M. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (10) :1480-1485

[38] Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency [J].

Grange, Steven ;

Bekri, Soumeya ;

Artaud-Macari, Elise ;

Francois, Arnaud ;

Girault, Christophe ;

Poitou, Anne-Laure ;

Benhamou, Ygal ;

Vianey-Saban, Christine ;

Benoist, Jean-Francois ;

Chatelet, Valerie ;

Tamion, Fabienne ;

Guerrot, Dominique .

LANCET, 2015, 386 (9997) :1011-1012

[39] Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab [J].

Green, Hefziba ;

Harari, Emanuel ;

Davidovits, Miriam ;

Blickstein, Dorit ;

Grossman, Alon ;

Gafter, Uzi ;

Gafter-Gvili, Anat .

RENAL FAILURE, 2014, 36 (07) :1119-1121

[40] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome [J].

Greenbaum, Larry A. ;

Fila, Marc ;

Ardissino, Gianluigi ;

Al-Akash, Samhar I. ;

Evans, Jonathan ;

Henning, Paul ;

Lieberman, Kenneth V. ;

Maringhini, Silvio ;

Pape, Lars ;

Rees, Lesley ;

van de Kar, Nicole C. A. J. ;

Vande Walle, Johan ;

Ogawa, Masayo ;

Bedrosian, Camille L. ;

Licht, Christoph .

KIDNEY INTERNATIONAL, 2016, 89 (03) :701-711

← 1 2 3 4 5 6 7 8 9 →